newsfilter
← Latest News
GlobeNewswire·

TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics

  • Faruqi & Faruqi, LLP is investigating potential securities claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD).
  • Tvardi shares fell over 80% on Monday, October 13, 2025, following disappointing preliminary data from the Phase 2 REVERT clinical trial for TTI-101 in idiopathic pulmonary fibrosis.
  • The study aimed to assess safety, pharmacokinetics, & lung function but failed to meet its goals based on exploratory efficacy results.
  • Preliminary data indicated that percent predicted Forced Vital Capacity (FVC) was lower in placebo-treated patients compared to those receiving TTI-101.
  • Investors who suffered significant losses are encouraged to contact partner James (Josh) Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss legal options.
  • Additional information regarding the investigation is available at www.faruqilaw.com/TVRD.